Skip to main content

Team Style


Prof. Wei Jia

  • 2013-2019  Tenured and Full Professor at University of Hawaii, and Associate Director of the University of Hawaii Cancer Center
  • 2008-2013  Tenured and Full Professor at the University of North Carolina at Greensboro and Co-Director of UNCG Center for Translational Biomedical Research
  • 2003-2008  Professor and Vice Dean for Research, School of Pharmacy, Shanghai Jiao Tong University 
  • 2001-2003  Professor and Executive Vice Dean at College of Pharmaceutical Science, Tianjin University
  • 1998-2003 Founder, Chairman, and CEO of Wofen (Tianjin) Pharmaceutical Co., Ltd.


Prof. Wei Jia currently serves as a chair professor at the School of Chinese Medicine, Hong Kong Baptist University, and director of the Hong Kong Traditional Chinese Medicine Phenome Research Centre (HKPR), who is also a adjunct professor at the Shanghai Jiao Tong University School of Medicine.


Prof. Jia has been specializing in scientific research and industrialization in the pharmacy and medical sectors for over two decades. He has founded and assisted the operation of an array of academic or research and development (R&D) institutes funded by businesses, including medical centers for discipline-based cross-transformation research, clinical multi-omics research platforms, and R&D institutes of traditional Chinese medicines and natural drugs.


He has published over 500 scientific papers on international academic periodicals, which have been quoted for more than 37,000 times, with an h-index of 92 on Google Scholar, and 10 academic books, with the ownership of 20 invention patents. As the chief scientist, Jia led and completed numerous scientific research programs, including National Basic Research Program of China (973 Program), NIH R01 project, NCI/NIH U01 project, and many others. His research findings were published on top-level academic journals, such as Science, Nature Reviews Drug Discovery, Cancer Cell, Science Translational Medicine, Blood, Proceedings of the National Academy of Sciences USA (PNAS), among other high-level international learned periodicals. Finding of his study on nephrotoxicity among children caused by interaction between milk-based infant formula contaminated with melamine and intestinal bacteria in children was on the list of Science's Top 10 Breakthroughs of 2013.




Core Team


Guoxiang Xie

Co-founder/Chief Operating Officer

Doctor of Medicine at Shanghai Jiao Tong University, and a Shenzhen Overseas High-Caliber Personnel. With nearly 20-year research experience in metabolomics and translational medicine, Xie once worked at Shanghai Jiao Tong University’s Shanghai Center for Systems Biomedicine, University of North Carolina’s Center for Translational Biomedical Research, and University of Hawaii Cancer Center, prior to joining HMI.

Xie has founded and is running a one-stop, automated, and standardized metabolomics service platform based on the combination of gas chromatography (GC) and mass spectrometry (MS). He has also developed a metabolic disease diagnostic technology based on metabolomics. In addition, Xie has published 4 academic books in Chinese and 2 in English (chapter drafting), as well as nearly 150 SCI papers on world’s top-ranking journals. His papers have been cited for over 11500 times with an h-index of 56 on Google Scholar. He also owns over 10  patents. Xie has led or participated in many scientific research programs in China and the US, including National Basic Research Program of China (973 Program), NIH R01 project, NCI/NIH U01 project, etc.



Jingchao Lin

Chief Marketing Officer

Doctor at Shanghai Jiao Tong University, and Off-campus Mentor at the Graduate School of Chinese Academy of Agricultural Sciences. Lin is currently a member of Biophysical Society of China’s Intestinal Flora Academic Subgroup, Chinese Nutrition Society’s Subgroup of Nutrition and Omics Technology, Special Committee of Analytical Pharmacology at the Chinese Pharmacological Society, and Youth Committee of the Professional Committee on Tumor Metabolism at the China Anti-cancer Association. 


Dr. Lin has been focusing on the application and marketing of metabolomics and intestinal flora technology in the biomedical sector for a long time. She was a Product Manager for PerkinElmer in China, a Senior Technical Engineer at Sciex, and an Account Manager for Agilent in Shanghai.




Kejun Zhou

R&D Director

Doctor of Biology at Shanghai Jiao Tong University and a Talent in the Shenzhen High-Level Talent Plan


Zhou is responsible for the development of diagnostic reagent-related products, who has been specialized in early-diagnosis research of digestive disorders in children. He has undertaken and finished research projects funded by National Natural Science Foundation of China, Natural Science Foundation of Shanghai, and others.








专注 创新                     快乐 成长
Gathering world’s top scientists and medical elites from metabolomics and mass spectrometry, clinical medicine, bioinformatics, and more sectors, HMI focuses on turning its patents and scientific research payoffs into products, and steers constant innovation in precision medicine and diagnostics. Its founding team boasts nearly two decades of world-class scientific research experience in the metabolomics sector as well as dominant innovations in the world, hence laying a solid foundation of innovation and talent reserve for China based on metabolomics and biomedicine .